Background Pertussis vaccination has been alleged to cause an encephalopathy that involves seizures and subsequent intellectual disability. In a previous retrospective study, 11 of 14 patients with so-called vaccine encephalopathy had Dravet syndrome that was associated with de-novo mutations of the sodium channel gene SCN1A. In this study, we aimed to establish whether the apparent association of Dravet syndrome with vaccination was caused by recall bias and, if not, whether vaccination aff ected the onset or outcome of the disorder.
Introduction
Claims of causal associations between vaccination and neurological disorders, most recently autism, have societal consequences for vaccination uptake and also have medicolegal implications. 1 Despite extensive epidemiological studies showing no relation between vaccination and permanent neurological disease, [1] [2] [3] [4] perception of causality is hard to eliminate.
In a retrospective study, most patients with suspected so-called vaccine encephalopathy-a poorly defi ned disorder that causes seizures and intellectual impairment in infants, with onset after vaccination-had clinical features typical of the severe epileptic encephalopathy Dravet syndrome. 5 Moreover, most patients had de-novo mutations of the sodium channel gene SCN1A, thus questioning the idea that the vaccination was the primary cause of the encephalopathy. We therefore concluded that in these patients Dravet syndrome was misinterpreted as a syndrome that had an acquired cause (vaccination) because the phenotype was not recognised and a family history of epilepsy was absent. Pertussis vaccination was usually suspected to be the cause of seizures and intellectual disability because the vaccination often causes minor distress (including fever and irritability, particularly with the old cellular preparation) 6 and carries an increased risk of benign febrile seizures. 6, 7 The absence of family history, and severe illness in a previously healthy infant, reinforced the misconception that pertussis vaccination caused the encephalopathy.
Dravet syndrome (also known as severe myoclonic epilepsy of infancy; SMEI) is characterised by onset of seizures at around 6 months of age. Initial seizures are usually prolonged convulsions, either generalised or hemiclonic, often triggered by fever. Other seizure types that subsequently develop include myoclonic, partial, absence, and atonic seizures. From the second year of life, intellectual development in these infants begins to plateau or regress, resulting in intellectual disability. 8 About 70-80% of children with Dravet syndrome have mutations in SCN1A, of which 95% are de novo. [9] [10] [11] Diphtheria-tetanus-pertussis (DTP) vaccination, typically given at 2 months, 4 months, and 6 months of age, has been reported to precede the onset of Dravet syndrome or to apparently trigger further seizures in children who already have the disorder. 8, 12 In this setting, families typically blame vaccination for the illness. Further vaccination might be advised against by the physician or refused by the family.
Although our earlier report suggested that vaccine encephalopathy was not a real disorder, 5 there remains a possibility, because of the apparent temporal association, that DTP vaccination might sometimes trigger the onset of Dravet syndrome. Reports from families of aff ected children might be subject to recall bias because families might suspect an association between the onset of Dravet syndrome and vaccination. If, however, the observation of the temporal association is valid, a gene-environment interaction might be occurring.
We aimed to assess, in patients with Dravet syndrome and a known mutation of SCN1A, whether there was a genuine temporal association of seizure onset with vaccination, by use of source records to avoid recall bias. We also assessed whether patients who had onset of Dravet syndrome shortly after vaccination had any specifi c clinical, molecular, or outcome diff erences that could suggest the disorder in these patients represents a separate entity. Such data might have important consequences for the advice given to parents regarding vaccination.
Methods

Patients
We included patients with Dravet syndrome from our study on infantile epileptic encephalopathies. 10 The diagnosis of Dravet syndrome includes patients who were previously diagnosed with classical SMEI or the borderline variant (severe myoclonic epilepsy of infancy borderline), in which certain features deemed to be essential for a diagnosis of SMEI are absent. 10 We sought validated source data (the date of the fi rst seizure and the dates of vaccinations) for patients with Dravet syndrome who have a mutation in SCN1A and in whom the fi rst seizure was a convulsion. We excluded patients whose fi rst seizure was a myoclonic or absence seizure because the exact dates of these are hard to verify.
The study was approved by the Human Research Ethics Committee of Austin Health. Written informed consent was obtained from all patients or their parents at enrolment in our previous study.
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Procedures
The date of each fi rst seizure was validated by use of hospital charts or fi les from the patients' family doctor or specialist. Exact dates of each of the DTP vaccinations were obtained from original medical records or the child's health-care booklet, which was retained by the parents. These booklets were stamped or signed and dated at the time of the vaccination by the health-care professional who gave the vaccine. Because the exact composition of vaccinations has changed over time, we documented whether the patients received whole-cell or acellular forms of pertussis vaccine.
From the source data we assessed the number of days between the fi rst convulsive seizure and the previous vaccination. A day was defi ned as midnight to midnight because the date but not the time of vaccination was documented in the source data. The day of vaccination was day 0, and all seizures that occurred on day 0 occurred between the time of vaccination and midnight of the day of vaccination. Day 1 was from midnight of the day of vaccination to midnight of the next day. We separated patients into two groups according to whether seizure onset occurred shortly after vaccination (vaccinationproximate group) or not (vaccination-distant group).
We analysed the clinical characteristics and distribution of molecular lesions in the two groups to establish whether the vaccination-proximate group had a diff erent outcome or other distinguishing clinical or molecular features compared with the vaccination-distant group. Intellectual outcome was classifi ed, according to a detailed assessment of developmental milestones and present functioning of each patient, as normal intellect (documented normal educational achievement), mild intellectual disability (defi nite mild intellectual impairment), moderate intellectual disability (limited speech and cognition but able to do some aspects of daily living), or severe intellectual disability (limited or no speech and dependent for activities of daily living-ie, going to the toilet and dressing). 10 Classifi cation was done by assessors masked to mutation type or relation to vaccination. For binary analyses, we grouped together children with normal intellect and mild intellectual disability and compared them with those with moderate or severe intellectual disability. Intellectual regression was defi ned as prolonged (4 weeks or more) or permanent loss of skills and was coded as present or absent.
Numbering of SCN1A mutations was taken from the start codon ATG of the full-length SCN1A mRNA sequence (Genbank accession number AB093548). Mutations were divided into missense mutations or others from which markedly abnormal protein was predicted, including truncation, frameshift, and splicesite mutations. Such other mutations have been reported only in patients with Dravet syndrome or related severe epilepsies and never in control individuals. 13 Missense mutations were classed as causative if they had been previously reported in Dravet syndrome or if they predict a non-conservative amino acid change in an evolutionarily conserved residue and are absent from single nucleotide polymorphism databases of healthy individuals. Certain missense mutations cause milder epilepsy syndromes and rarely some missense variants occur in healthy individuals. 13 To establish whether outcome was worse in patients who received vaccination after seizure onset, we compared outcomes according to whether or not patients had received further vaccinations.
In a post-hoc analysis, we examined whether nonmissense mutations were associated with earlier age at onset, and whether these mutations or earlier age at onset were associated with worse outcome.
Statistical analysis
Patients with missing data were excluded from the relevant analyses. Independent-sample t tests were done to examine diff erences in age at onset. Diff erences in other characteristics between groups were tested using the Fisher's exact test. Statistical signifi cance was tested at the 5% level using two-tailed tests. All analyses not stated as post-hoc were prespecifi ed. The number of days used to defi ne the vaccination-proximate group was calculated after viewing the summary data but before the analyses were undertaken.
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Results
We identifi ed 127 patients with Dravet syndrome from our previous study, 10 101 of whom had a confi rmed mutation in SCN1A. Six of these patients were excluded because their fi rst seizure was a myoclonic or absence seizure. Data for 84 of these 95 patients have been published previously. 5, 10, [14] [15] [16] Validated data (ie, the date of the fi rst convulsion and the vaccination dates) were obtained from source data and were available for 40 of the 95 patients, including six patients from our earlier report on vaccine encephalopathy. 5 The 40 patients with validated data did not diff er from the 55 patients without validated data in terms of mean age at onset, outcome, syndromic diagnoses, or mutation types (data not shown).
The 40 patients with validated data had a median age of 5·4 years (IQR 3·2-8·0 years; range 11 months to 27 years) at assessment. Mean age at seizure onset was 5·5 months (SD 1·9). The median age was 2·1 months (IQR 1·9-2·5) at the fi rst vaccination, 4·3 months (4·1-4·8) at the second vaccination, and 6·8 months (6·2-8·7) at the third vaccination. Three patients had their fi rst seizure before their fi rst vaccination; the remaining 37 had their fi rst seizure after at least one DTP vaccination. Inspection of these data showed a clear temporal peak (fi gure 1), which led us to classify children as vaccination-proximate if they had their fi rst seizure on days 0 or 1, and vaccinationdistant if their fi rst seizure occurred 2 days or more after a vaccination. 12 of 40 patients had seizure onset either on the day of vaccination (n=5) or during the fi rst day postvaccination (n=7) and were thus defi ned as vaccinationproximate. The patients in the vaccination-distant group had seizure onset from day 2 to day 98 after vaccination (n=25) or before the fi rst vaccination (n=3).
Of the 37 patients who had at least one vaccination before seizure onset, eight had their fi rst seizure after Analysis of the SCN1A mutations in the 40 patients with validated data revealed 12 missense and 28 other mutations (18 truncation, 9 splice site mutations, and 1 deletion of exons 21-26; fi gure 2). Two mutations (IVS4+1G>A and S1516X) were found in patients in both the vaccination-proximate group and the vaccinationdistant group (webappendix).
From assessment of fi gure 1, one could argue that patients with their fi rst seizure 2-5 days after vaccination should also be included in the vaccination-proximate group. Post-hoc, the comparison of vaccination-proximate and vaccination-distant groups was rerun using an extended defi nition of vaccination-proximate (seizure onset day 0-5). The mean age at onset was 20·5 weeks (SD 6·4) in the vaccination-proximate group and 26·4 weeks (8·7) in the vaccination-distant group (diff erence 5·9 weeks, 95% CI 0·9-11·0; p=0·02). Using this extended defi nition, seven of 17 patients in the vaccination-proximate group and nine of 23 in the vaccination-distant group had intellectual regression (p=1·0), and 12 of 17 patients in the vaccination-proximate group and 15 of 23 in the vaccination-distant group had moderate or severe intellectual disability (p=1·0).
We also assessed whether age at onset or mutation type was associated with worse outcome, irrespective of proximity to vaccination. 13 of 40 patients had normal intellect or mild intellectual disability (mean age at onset 21·3 weeks [SD 7·7]) and 27 of 40 patients had moderate or severe intellectual disability (25·1 weeks [8·4]; p=0·2). The mean age at onset was 21·9 weeks (8·6) for those with intellectual regression and was 25·2 weeks (8·0) for those without (p=0·2). There was no diff erence between patients with missense mutations and those with other mutations in age at onset (other 23·6 weeks [7·0] vs missense 24·5 weeks [11·0]; p=0·8), moderate or severe intellectual disability (other 20 of 28 vs missense 7 of 12; Fisher's exact p=0·5), or occurrence of regression (other 13 of 28 vs missense 3 of 12; Fisher's exact p=0·3).
Most children receive three sequential identical vaccinations. However, in our sample the onset of seizures resulted in exclusion of the pertussis component from subsequent vaccinations in some patients. In a post-hoc analysis, we investigated the association between vaccination after seizure onset and intellectual disability. Complete vaccination data for the fi rst year were available in 37 of 40 patients, 12 of whom had normal or mildly 
Discussion
About one-third of patients with Dravet syndrome had disease onset less than 2 days after vaccination, and the mean age at onset in these patients was signifi cantly lower than that of patients whose disease onset was vaccination-distant. Universal vaccination in infancy is an emotive issue, in which science, societal views, and social policy are sometimes poorly aligned. 1 At present, there is much attention on the debate regarding vaccination and autism; [17] [18] [19] this attention is similar to the earlier intense debate regarding the role of pertussis vaccination and so-called vaccine encephalopathy. We previously reported a retrospective analysis in which 12 of 14 patients with presumed vaccine encephalopathy in fact had previously unrecognised Dravet syndrome, 11 of whom had mutations in SCN1A. 5 This showed that vaccination was wrongly blamed as an acquired cause of a genetic disorder, 20, 21 and the hypothesis that vaccination was the causal factor in our cohort could be rejected. However, the possibility that vaccination triggered the onset of Dravet syndrome, causing a temporal shift (ie, brought forward an inevitable onset), 22 or resulted in worse neurological outcome in these patients could not be excluded.
Recall bias can be a major factor in reporting of catastrophic disorders, and our impression was that certain cases of Dravet syndrome that were not clearly temporally associated with vaccination were nevertheless attributed to vaccination. Here, by examining a cohort of patients with Dravet syndrome who were not selected according to temporal relation to vaccination, we have confi rmed the previous clinical reports that the onset of Dravet syndrome might occur shortly after vaccination. 8, 12 In our cohort, in which recall bias was minimised by reliance on source records, 30% of patients with Dravet syndrome who had SCN1A mutations had seizure onset shortly after vaccination.
We used a data-driven approach to identify days 0-1 as the at-risk period. The period of apparent vulnerability to onset of epilepsy after DTP vaccination has not been clearly defi ned, although 24-72 h periods are generally used. 7, [23] [24] [25] [26] [27] Our data was precise regarding the date, but not the hour, of vaccination and seizure onset. Because immunisations were likely to have been given in working hours, the at-risk period seems to be within 40 h of vaccination.
The mean age at disease onset was 7·8 weeks earlier in the vaccination-proximate group than in the vaccinationdistant group, but all other clinical and outcome measures did not diff er between groups (table 1). The mean age at onset in the vaccination-distant group was 26 weeks, which is similar to that quoted for patients with Dravet syndrome (5·5-6·0 months). 8, 28, 29 Our fi ndings show that, although vaccination might sometimes seem to trigger the onset of Dravet syndrome, there is no evidence that patients in the vaccination-proximate group had a diff erent disorder from those in the vaccination-distant group. In particular, the similarity in clinical and outcome measures between patients in the vaccination-proximate group and those in the vaccination-distant group is not consistent with vaccination itself aff ecting the severity of IVS4+1G>A S1516X the disorder. Using a diff erent approach in a population cohort, Goodman and colleagues 22 found evidence for a temporal shift of onset (but not of frequency) of infantile spasms in previously normal children after DTP or diphtheria and tetanus vaccination.
Molecular lesions also did not seem to diff er in their type (missense versus other) or distribution within the protein between the vaccination-proximate and vaccination-distant groups (fi gure 2). The same mutations occurred in both groups on two occasions, further highlighting the similarity of the groups.
Despite the absence of signifi cant diff erence, we wondered whether the higher number of non-missense mutations in the vaccination-proximate group could explain the earlier age at onset, but analysis of age at onset with respect to mutation type did not support this suggestion. We also examined whether earlier age at onset or presence of non-missense mutations were associated with intellectual disability or regression, and no associations were found.
Seizure onset in Dravet syndrome commonly occurs in the setting of fever. Only one third of patients had fever documented with the initial seizure, suggesting that vaccination might work through an alternative mechanism to trigger seizure onset earlier than might have occurred otherwise.
There are several limitations to this study. To study a homogeneous cohort, we assessed only patients with Dravet syndrome and SCN1A mutations who had been referred to the Epilepsy Research Centre, Melbourne, Australia. This approach might have resulted in some bias in the study. Also, our fi ndings might not apply to the 20-30% of patients with Dravet syndrome who do not have SCN1A mutations. Because of the problem of recall bias, we chose to include only patients with validated vaccination and onset data. This limited the number of patients we could include in the analyses, and thus type 2 errors might have occurred. Finally, because our study was not a prospective evaluation with random assignment of vaccination, we cannot exclude the possibility that patients in the vaccination-distant group had an artifi cially later age at onset because vaccination occurs at fi xed times, typically at around 2, 4, and 6 months. However, this is unlikely because the mean age at onset in the vaccination-distant group was similar to that reported for patients with Dravet syndrome overall (ie, 6 months), whereas disease onset was at a mean of 18·4 weeks in the vaccination-proximate group.
There is increasing interest in examining gene-environment interactions in clinical research. Our study design and absence of a control group of patients with Dravet syndrome who did not have DTP vaccinations precluded us from examining a gene-environment interaction. However, our observation of an environmental eff ect (vaccination) temporally shifting the age at onset of an age-specifi c genetic neurological disease with no apparent eff ect on outcome suggests that Dravet syndrome would be an ideal model, both clinically and in experimental animals, with which to formally assess and examine the basis of such an interaction. If vaccination was withheld, the patients in the vaccination-proximate group would be expected to have had disease onset with the next substantial environmental trigger, be it fever, infection, or another stressor.
We therefore conclude that there is no rational basis for withholding DTP immunisation for potentially lethal childhood diseases for fear of causing Dravet syndrome or injuring the brain by a direct or presumed immunemediated mechanism. The fi nding that onset of seizures occurred after the fi rst, second, or third vaccination argues against a major role for immune sensitisation in which an initial immune challenge (ie, vaccination) has no eff ect but subsequent challenges have increasing eff ects. Outcome was not infl uenced by vaccination after clinical onset (table 2) , and thus vaccination does not seem to cause brain damage, although this analysis was post hoc and would ideally require confi rmation in a prospective study.
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